Introduction
============

Periprosthetic joint infection (PJI) following total joint replacement surgery is a devastating complication that is associated with poor functional outcomes[@B1] and a higher risk of all-cause mortality[@B2]. Staphylococci, the most common PJI pathogens, access the periprosthetic space either during the perioperative period or through hematogenous dissemination[@B3]. Recent reports suggest that antibiotic- resistant strains are becoming more common[@B4],[@B5].

Standard parenteral antibiotics for methicillin- susceptible staphylococcal PJI generally antistaphylococcal penicillins and cephalosporins, such as oxacillin and cefazolin respectively, Vancomycin and teicoplanin (outside of North America) are glycopeptide antimicrobials used to treat methicillin-resistant staphylococcal PJI. All of these medications have notable limitations in efficacy, and have not been demonstrated to reliably sterilize retained orthopedic implants in laboratory or clinical settings. Resistance to teicoplanin has been documented to occur in up to 9% of staphylococcal PJI[@B4] and nephrotoxicity has been associated both with systemic use and (less commonly) within antibiotic cement spacers[@B6],[@B7]. Furthermore, vancomycin requires careful dose titration which can be difficult in non-acute care settings.

An alternative to the above antibiotics is daptomycin, a cyclic lipopeptide that has selective activity against aerobic, anaerobic, and facultative gram-positive bacteria. Daptomycin coordinates with calcium ions and bacterial phospholipids to depolarize bacterial cell membranes, producing a rapid bactericidal effect[@B8]. Daptomycin has a simplified dosing schedule, has few drug-drug interactions due its lack of metabolism by cytochrome P450 or other hepatic enzymes[@B9], and is far less nephrotoxic than vancomycin[@B10]. Daptomycin is active against most MRSA. There is limited evidence that daptomycin may improve outcomes in MRSA infections, relative to vancomycin monotherapy. For instance, in a matched cohort of 262 patients with MRSA bacteremia, daptomycin was associated with less clinical failure and lower mortality[@B11]. *In vitro*[@B12], and in animal models[@B13]-[@B15], daptomycin shows better ability than vancomycin to kill MRSA in biofilms, particularly when combined with rifampin. Despite its higher cost, daptomycin may remain cost-effective in treating systemic MRSA infections[@B16],[@B17]; since the introduction of generic daptomycin in 2016, acquisition costs have decreased significantly.

To date, small series of fewer than twenty consecutive PJI patients receiving daptomycin as their primary treatment antibiotic have been published. A recent paper noted no differences in outcome, but an increased safety profile, in patients receiving daptomycin (versus vancomycin) for empiric postoperative antibiotic therapy; in this study empiric daptomycin was given for only 6 days[@B18]. No larger studies have compared definitive treatment with daptomycin versus other antimicrobials across a single cohort. Chang[@B19] evaluated 16 PJI patients who could not receive vancomycin therapy either due to bacterial resistance, previous treatment failure with vancomycin, or stage 3 or 4 renal disease. They found that treatment success when combined with surgical treatment was 87.5% with no severe side effects reported.

Due to its antimicrobial profile and documented rapid penetration into bone and synovial tissue during joint replacement surgery[@B20], daptomycin may have a promising role in the treatment of PJI. We therefore present our experience with daptomycin in the treatment of both acute and chronic staphylococcal PJI with minimum 2-year follow-up.

Methods
=======

Institutional Review Board approval was obtained prior to study. We queried a retrospectively gathered periprosthetic joint infection database in our tertiary orthopedic institution to identify all total hip arthroplasty (THA) and total knee arthroplasty (TKA) cases with staphylococcal PJI from January 2009 to February 2016. To accomplish this, hip and knee patients with an ICD-9-CM code of 996.66 or ICD-10-CM codes of T84.51\*, T84.52\*, T84.53\*, T84.54\* for PJI were first identified. These patients were then cross-referenced with a subset of ICD-9-PCS or ICD-10-PCS codes and CPT billing codes to identify those who underwent either implant removal in the setting of a two-stage revision or a debridement with implant retention (DAIR). All qualifying cases then underwent detailed chart review to include only those that met Musculoskeletal Infection Society (MSIS) diagnostic criteria for PJI prior to treatment[@B21]. Staphylococcal PJI was defined as at least one deep tissue culture growing a microorganism from the genus *Staphylococcus*. Acute PJI was defined as a PJI diagnosed fewer than 90 days after arthroplasty.

Through chart review, patient demographics including height, weight, preoperative lab values within two weeks of surgery, comorbidities, prior arthroplasty history, clinical presentation and symptoms were collected. Charlson comorbidity index (CCI) scores[@B22] were calculated for each patient and then categorized into groups of score of 0, 1-2, and ≥ 3. Diagnostic criteria including serum and synovial inflammatory markers, findings from imaging studies, surgical procedure details and all microbiology results were collected. All patients were assessed by a board-certified infectious disease specialist and managed by a multidisciplinary team during admission. Intraoperatively, 5 or more joint tissue samples were collected and intraoperative antibiotics were held prior to culture collection. Patients underwent implant removal or DAIR according to surgeon preference and clinical indications. For DAIR, the volume of irrigation, use of antiseptics and exchange of modular components was left to the discretion of the surgeon. When implants were removed, a polymethylmethacrylate (PMMA) spacer containing vancomycin and an aminoglycoside (either gentamicin or tobramycin) was placed. The type of PMMA used and the dosage of antibiotic were left to the discretion of the surgeon.

Following surgery, all patients received intravenous antibiotic therapy until postoperative day 42. Vancomycin and a broad-spectrum beta-lactam agent were generally given empirically immediately following surgery, and then antibiotics were adjusted according to microbiologic results. Antibiotic regimens were selected in a non-randomized multifactorial way as follows: while most patients with methicillin-sensitive staphylococcal PJI received anti- staphylococcal beta-lactams (cefazolin or oxacillin), some were treated with daptomycin because of allergy or to provide a convenient home dosing schedule. Among patients with methicillin- resistant pathogens, daptomycin or vancomycin were selected based on a variety of factors including: evidence of higher risk of vancomycin-induced kidney injury, ability to tolerate and participate in vancomycin dose titration at home, ability to achieve therapeutic levels of vancomycin at home, insurance coverage considerations for daptomycin, and possible potency differences of daptomycin versus vancomycin in MRSA with vancomycin MIC \> 1 ng/microliter. In addition, daptomycin was occasionally started in cases of vancomycin nephrotoxicity or other intolerance. Data on daptomycin dose was not captured for many patients in this cohort. Daptomycin was dosed between 6 and 9 mg/kg intravenously once daily, often rounded up to the nearest 250mg. No patient received daptomycin at a dose of more than 9 mg/kg.

Following hospital discharge, antibiotic therapy was provided until postoperative day 42 (6 weeks in total) via an outpatient infusion pharmacy, an outpatient infusion center, or an inpatient rehabilitation (although such facilities rarely provided daptomycin due to economic constraints). Standard blood tests were performed weekly to assess for signs of nephrotoxicity, hepatotoxicity, myelotoxicity, and in the case of daptomycin, myotoxicity as well; vancomycin trough levels were monitored at least once per week. For DAIR cases, intravenous antibiotic therapy was combined with oral rifampin therapy (at a daily dose of 600mg), and was followed by oral antibiotic suppression that continued for a minimum of 3 months. Rifampin was provided for no less than 6 weeks, and no more than 6 months.

For two-stage exchange, a minimum 2-week antibiotic holiday preceded reimplantation, often but not always confirmed with preoperative aspiration or intraoperative frozen sections, and apart from 24 hours of perioperative prophylaxis, antibiotics were not routinely prescribed postoperatively.

For PJI cases treated with DAIR, success was defined as prosthesis retention at 2-year follow up after the last surgical procedure. Therefore, patients who underwent multiple DAIR procedures within the same admission, but still retained their original non- modular components 2 years later, were considered successful. For patients treated with two-stage exchange, success was defined as retention of the newly implanted prosthesis with no further surgical procedures secondary to infection in the two years following reimplantation[@B23]. Clinical outcome was obtained through chart review of follow up visits with either the orthopedic surgeon or infectious disease specialist.

Statistics
----------

Continuous variables such as BMI and age are presented as the mean and standard deviation (SD) and were compared using a Student t test or Mann-Whitney U test. Categorical variables such as sex, parenteral antibiotics and intervention performed are presented as frequencies and were compared using the chi-square test or the Fisher exact test. Logistic regression analyses were performed to identify risk factors associated with treatment outcome. The sample population was normally distributed. All tests were 2-sided. Significance was defined as p \< 0.05. Kaplan-Meier survivorship curves were generated for 2-year follow-up with 95% confidence interval (CI). Statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC).

Results
=======

341 patients met inclusion criteria for staphylococcal PJI within the study period. 158 patients were infected with methicillin sensitive *Staphylococcus aureus* (MSSA), 60 with MRSA and 123 with coagulase-negative *Staphylococcus* (CONS). 77 patients (22.6%) were treated with daptomycin. There was no significant difference in patient demographics, patient comorbidities or singular bacterial species between daptomycin and non-daptomycin groups \[Table [1](#T1){ref-type="table"}\]. The overall success rate of staphylococcal PJI treatment was 66% and success rate of staphylococcal PJI treated with daptomycin was 64%.

With regard to treatment success, two-stage exchange patients had a significantly increased rate of treatment success (154 of 200, 77%) compared to DAIR (74 of 141, 52%; p\<0.0001) at 2 years. In multivariate regression, bacterial species were found to be significantly associated with treatment outcome only in the DAIR group, with CONS (odds ratio=5.58, p = 0.007) and MSSA (odds ratio=3.68, p=0.031 respectively) yielding significantly better rates of treatment success rates compared to MRSA \[Table [2](#T2){ref-type="table"}\]. CCI scores were significantly associated with treatment outcomes in both DAIR and two-stage groups, with CCI scores ≥3 being associated with significantly higher treatment failure rates in both pairwise comparisons (p=0.009, p=0.012, respectively) and regression analysis (p=0.003, 0=0.014, respectively).

Treatment success with two-stage use did not significantly differ in daptomycin (34 of 50, 68%) versus non-daptomycin groups (118 of 150, 79%; p=0.126) \[Table [3](#T3){ref-type="table"}\]. Treatment success with DAIR did not significantly differ in daptomycin (15 of 27, 56%) versus non-daptomycin groups (59 of 114, 52%; p=0.72) \[Table [3](#T3){ref-type="table"}\]. When holding patient demographics, and bacterial species constant, treatment with daptomycin was not significantly associated with DAIR or two-stage treatment success (p=0.170, p=0.301, respectively) \[Table [2](#T2){ref-type="table"}\]. For patients who did not achieve treatment success with daptomycin, no daptomycin-resistant strains were detected in subsequent cultures.

The two-year survivorship for DAIR patients treated with daptomycin was 55% (95% CI, 36%-74%; Fig. [1](#F1){ref-type="fig"}) and 53% (95% CI, 43%-62%; Fig. [1](#F1){ref-type="fig"}) for non- daptomycin patients. The two year survivorship for two-stage exchange patients treated with daptomycin was 71% (95% CI, 56%-86%; Fig. [2](#F2){ref-type="fig"}) and 85% (95% CI, 78%-91%; Fig. [2](#F2){ref-type="fig"}) for non-daptomycin patients. There were no significant differences in survivorship when stratified by daptomycin use in the DAIR group (p=0.711) or two-stage exchange group (p=0.121).

Six patients (7.8%) had complications associated with daptomycin use. Two patients that had undergone two-stage exchange followed by daptomycin treatment were diagnosed with eosinophilic pneumonitis, one occurring at 6 days and the other 40 days after commencement of therapy. Both cases resolved following cessation of daptomycin. Furthermore, four patients exhibited serum elevations of creatine phosphokinase and two were subsequently diagnosed with rhabdomyolysis within two weeks of treatment, prompting cessation of daptomycin and rapid recovery. One patient in the daptomycin group that underwent a two-stage exchange died three days following explantation due to cardiac arrest, but daptomycin was not considered to be associated with the mortality.

Discussion
==========

This study represents the single largest cohort of PJI patients treated with daptomycin to date. In our series, daptomycin treatment following DAIR or two-exchange revision was no more or less effective than comparable antibiotics. Daptomycin was tolerated well in 92% of our patient cohort: the convenient dosing, lack of nephrotoxic risk, and putative enhanced anti-staphylococcal potency of daptomycin make it an appealing choice for postoperative antibiotic therapy in PJI. However, these advantages must be carefully weighed against higher costs and occasional serious side effects.

Two patients in our cohort developed eosinophilic pneumonitis, an unusual and poorly- understood complication associated with daptomycin. The largest study to date of complications secondary to daptomycin administration found, in 11,557 patients, an estimated incidence of eosinophilic pneumonitis of 0.03% [@B24]. A review of the US FDA Adverse Event Reporting System database identified 7 definite, 13 probable, and 38 possible cases of daptomycin-induced eosinophilic pneumonia[@B25]. A recent literature search in PubMed confirmed 32 case reports meeting formal criteria for eosinophilic pneumonitis, with most resolving following cessation of daptomycin. Given the rarity of published reports of this unusual pulmonary entity, it may be underdiagnosed. Further study is required to identify risk factors for eosinophilic pneumonitis and to best diagnose it the PJI cohort.

Four patients in our daptomycin cohort exhibited increases in serum creatine phosphokinase levels, with two developing clinical rhabdomyolysis. The association between daptomycin use and muscle damage has been well demonstrated: phase III clinical trials reported a 2.8% incidence of elevated CPK levels and 0.2% incidence of myopathy[@B26]. The mechanism of action has been described *in vitro* and is associated with daptomycin-induced interruption of myocyte membrane electrical potentials, leading to inhibition of muscle contractions and pain[@B27]. Regular and prompt serum measurement of creatine phosphokinase (CPK) is recommended[@B28]. Rhabdomyolysis remains a rare complication of daptomycin therapy as long as daptomycin is infused every 24 hours and CPK is monitored regularly.

We acknowledge limitations in this study. Daptomycin use was often subject to patient insurance coverage, and although we did not identify any difference between patients who received and did not receive daptomycin in demographic data, pathogen, or surgical strategy, we acknowledge that possible selection bias or confounding effects are possible. Furthermore, the surgical indications for DAIR and two-stage revision were not always clearly defined, making surgical treatment a potential confounder in determining why treatment failed. DAIR procedures were not standardized by type and volume of irrigation utilized. Similarly, the type of cement and dosage of antibiotic in two-stage revisions was not standardized, nor were the diagnostic criteria for confirming eradication and clearance for reimplantation. Although the lack of treatment standardization in PJI is not unique to our study[@B29]-[@B32], we acknowledge that this makes interpretation of a single variable (the intravenous antibiotic) difficult to interpret with regard to treatment outcome. The formalization of PJI consensus criteria has improved treatment standardization in our institution over the past year and we plan to re-evaluate daptomycin performance on more recent cases treated by a smaller group of high volume revision surgeons.

There may be a role for including daptomycin in PMMA spacers, which requires further study. Kuo[@B33] reported 100% treatment success when daptomycin was included as 10% weight of a PMMA spacer followed by systemic therapy of 6mg/kg for 2 weeks. No significant side effects related to daptomycin were observed. Finally, the combination of daptomycin with rifampin, which has been linked to improved clearance of staphylococcal biofilm in multiple models of study[@B34], should be the target of future formal clinical investigations to determine if a clinical effect on outcomes and prevention of emergence of resistance is observed.

In conclusion, this study demonstrates that daptomycin can be safely utilized for the treatment of staphylococcal PJI, with treatment outcomes which appear similar to commonly used comparator antimicrobials. The treatment success rates overall for both DAIR and two-stage cohorts were comparable but lower than contemporarily reported rates. Although eosinophilic pneumonitis and myotoxicity are rare complications of daptomycin therapy, we identified several cases in our cohort and advise awareness of these unusual entities.
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###### 

Univariate analyses of patient characteristics according to surgical treatment and antibiotic therapy

                             Debridement and Implant Retention                Two-Stage Exchange                                                   
  -------------------------- ----------------------------------- ------------ -------------------- -- ------------- ------------- ------- -- -- -- -------------
  **Age**                    63.8 ± 12.5                         66.7 ± 8.8   0.168                   65.2 ± 12.4   64.4 ± 11.7   0.707            
  **BMI**                    30 ± 6.8                            31.1 ±7.5    0.450                   29.8 ± 7      31.4 ± 7.8    0.198            
  **Sex \[M:F\]**                                                             0.812                                               0.456            
  Male                       62 (54.4)                           14 (51.9)                            90 (60.0)     27 (54.0)                      
  Female                     52 (45.6)                           13 (48.2)                            60 (40.0)     23 (46.0)                      
  **Acute PJI \[Yes:No\]**                                                    0.707                                               \-               
  Yes                        42 (36.8)                           11 (40.7)                            \-            \-                             
  No                         72 (63.2)                           16 (59.3)                            \-            \-                             
  **Bacterial Species**                                                                               **0.028\***                                  **0.004\***
  CONS                       36 (31.6)                           7 (25.9)                             65 (43.3)     15 (30.0)                      
  MRSA                       14 (12.3)                           9 (33.3)                             25 (16.7)     12 (24.0)                      
  MSSA                       64 (56.1)                           11 (40.7)                            62 (41.3)     21 (42.0)                      
  **CC Index**                                                                                        0.502                                        0.979
  0                          37 (32.5)                           9 (33.3)                             54 (36.0)     18 (36.0)                      
  1-2                        50 (43.9)                           9 (33.3)                             52 (34.7)     18 (36.0)                      
  3+                         27 (23.7)                           9 (33.3)                             44 (29.3)     14 (28.0)                      
  **Diabetes**               25 (21.9)                           7 (25.9)     0.656                   25 (16.7)     11 (22.0)     0.395            
  **RA**                     21 (18.4)                           6 (22.2)     0.652                   22 (14.7)     5 (10.0)      0.403            

BMI: body mass index, CONS: coagulase negative *Staphylococcus*, MRSA: methicillin resistant *Staphylococcus aureus*, MSSA: methicillin resistant *Staphylococcus aureus*, CC Index: Charlson comorbidity index. \* denotes p \< 0.05.

###### 

Regression outcomes according to surgical treatment

                                                 Odds Ratio   95% CI         P-value       
  ---------------------------------------------- ------------ -------------- ------------- --
  **[Debridement and Implant Retention]{.ul}**                                             
  **Age**                                        1.04         1.00 - 1.08    **0.041\***   
  **BMI**                                        1.04         0.98 - 1.11    0.095         
  **Male vs Female**                             0.69         0.32 - 1.48    0.342         
  **Daptomycin Use \[Yes vs No\]**               1.70         0.62 - 4.65    0.301         
  **Acute vs Non-Acute PJI**                     0.61         0.28 - 1.34    0.216         
  **Bacterial Species**                                                                    
  CONS vs MRSA                                   5.58         1.65 - 19.97   **0.007\***   
  MSSA vs MRSA                                   3.68         1.09 - 11.71   **0.031\***   
  **CC Index**                                                                             
  Score of 1-2 versus 0                          0.75         0.32 - 1.86    0.517         
  Score of 3+ versus 0                           0.20         0.06 - 0.53    **0.003\***   
                                                                                           
  **[Two Stage Exchange]{.ul}**                                                            
  **Age**                                        1.01         0.98 - 1.04    0.482         
  **BMI**                                        0.96         0.90 - 1.01    0.114         
  **Male vs Female**                             1.08         0.53 - 2.20    0.838         
  **Daptomycin Use \[Yes vs No\]**               0.58         0.27 - 1.26    0.170         
  **Bacterial Species**                                                                    
  CONS vs MRSA                                   1.83         0.7 - 4.81     0.219         
  MSSA vs MRSA                                   1.32         0.53 - 3.27    0.556         
  **CC Index**                                                                             
  Score of 1-2 versus 0                          0.53         0.21 - 1.30    0.164         
  Score of 3+ versus 0                           0.32         0.13 - 0.80    **0.014\***   

BMI: body mass index, CONS: coagulase negative *Staphylococcus*, MRSA: methicillin resistant *Staphylococcus aureus*, MSSA: methicillin resistant *Staphylococcus aureus*, CC Index: Charlson comorbidity index. \* denotes p \< 0.05.

###### 

Univariate analyses according to surgical treatment and outcome

                              Debridement and Implant Retention                 Two-Stage Exchange                                                  
  --------------------------- ----------------------------------- ------------- -------------------- -- ------------- ------------ ------- -- -- -- -------------
  **Age**                     65.8 ± 11.7                         62.8 ± 11.9   0.139                   65.2 ± 11.8   64 ± 13.4    0.503            
  **BMI**                     30.9 ± 7.5                          29.4 ± 6.1    0.202                   29.6 ± 6.1    32.4 ± 9.9   0.154            
  **Sex \[M:F\]**             38 : 36                             38 : 29       0.523                   89 : 63       28 : 20      0.979            
  **Daptomycin \[Yes:No\]**   15:59                               12 : 55       0.722                   34 : 118      6 : 32       0.126            
  **Acute PJI \[Yes:No\]**    25:49                               28:39         0.327                   \-            \-           \-               
  **Bacterial Species**                                                                                 **0.007\***                                 0.256
  CONS                        30                                  13                                    65            15                            
  MRSA                        7                                   16                                    25            12                            
  MSSA                        37                                  38                                    62            21                            
  **CC Index**                                                                                          **0.009\***                                 **0.012\***
  0                           27                                  19                                    62            10                            
  1-2                         36                                  23                                    53            17                            
  3+                          11                                  25                                    37            21                            

BMI: body mass index, CONS: coagulase negative *Staphylococcus*, MRSA: methicillin resistant *Staphylococcus aureus*, MSSA: methicillin resistant *Staphylococcus aureus*, CC Index: Charlson comorbidity index. \* denotes p \< 0.05.
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